ERBB2 and breast carcinoma: HER-2 amplification or strong overexpression correlate with increased risk for BM, and HER-2 positive breast cancer patients develop BM more frequently and rapidly than those with HER-2 negative tumors [24,25], especially if ER and PgR negative [26,27].